DE68925032T2 - Leukozyten-adhäsions-inhibitor. - Google Patents

Leukozyten-adhäsions-inhibitor.

Info

Publication number
DE68925032T2
DE68925032T2 DE68925032T DE68925032T DE68925032T2 DE 68925032 T2 DE68925032 T2 DE 68925032T2 DE 68925032 T DE68925032 T DE 68925032T DE 68925032 T DE68925032 T DE 68925032T DE 68925032 T2 DE68925032 T2 DE 68925032T2
Authority
DE
Germany
Prior art keywords
adhesion inhibitor
leucocyte adhesion
endothelial cells
endothelial
leucocyte
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68925032T
Other languages
English (en)
Other versions
DE68925032D1 (de
Inventor
Michael Gimbrone
Margaret Wheeler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Application granted granted Critical
Publication of DE68925032D1 publication Critical patent/DE68925032D1/de
Publication of DE68925032T2 publication Critical patent/DE68925032T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5421—IL-8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE68925032T 1988-08-15 1989-08-15 Leukozyten-adhäsions-inhibitor. Expired - Fee Related DE68925032T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23222488A 1988-08-15 1988-08-15
PCT/US1989/003479 WO1990001338A1 (en) 1988-08-15 1989-08-15 Leukocyte adhesion inhibitor

Publications (2)

Publication Number Publication Date
DE68925032D1 DE68925032D1 (de) 1996-01-18
DE68925032T2 true DE68925032T2 (de) 1996-04-25

Family

ID=22872317

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68925032T Expired - Fee Related DE68925032T2 (de) 1988-08-15 1989-08-15 Leukozyten-adhäsions-inhibitor.

Country Status (6)

Country Link
US (1) US5302384A (de)
EP (1) EP0429542B1 (de)
JP (1) JPH04500076A (de)
AT (1) ATE131071T1 (de)
DE (1) DE68925032T2 (de)
WO (1) WO1990001338A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH680001A5 (de) 1987-11-19 1992-05-29 Sandoz Ag
JPH05503512A (ja) * 1989-11-29 1993-06-10 ブリガム・アンド・ウイメンズ・ホスピタル 白血球接着阻害因子としての［ａｌａ　ｉｌ―８］↓７↓７
JPH05505391A (ja) * 1989-11-29 1993-08-12 ブリガム・アンド・ウイメンズ・ホスピタル 内皮由来のｉｌ―８
EP0616615B1 (de) * 1991-12-04 1998-08-12 The Biomedical Research Centre Limited Analoge des menschlichen Interleukin-8.
US7135458B1 (en) * 1995-11-15 2006-11-14 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interferon-γ inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use
US5811073A (en) * 1995-06-19 1998-09-22 President And Fellows Of Harvard College Method for radioisotopic detection and localization of inflammation in a host
DE19548630A1 (de) * 1995-12-12 1997-06-19 Schering Ag Verfahren zur Reinigung von rekombinantem Human-Interleukin - 8
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
DE10003811A1 (de) * 2000-01-28 2001-08-09 Sanorell Pharma Gmbh & Co Verfahren zur Herstellung eines serumhaltigen Kulturmediums für Zellen sowie dessen Verwendung

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5729949A (en) * 1980-07-30 1982-02-18 Nippon Koutai Kenkyusho:Kk Determination of sugar branch related to cancer and diagnostic technique of cancer
US4897348A (en) * 1983-08-25 1990-01-30 Sri International Recombinant materials and methods for producing human connective tissue-activating peptide-III and analogs thereof
DE3854536T2 (de) * 1987-05-04 1996-03-07 Dana Farber Cancer Inst Inc Interzellulare Adhäsions-Moleküle und deren Bindungsliganden.
US4840793A (en) * 1987-06-11 1989-06-20 Dana-Farber Cancer Institute Method of reducing tissue damage at an inflammatory site using a monoclonal antibody
US4797277A (en) * 1987-09-22 1989-01-10 Pharmacia Ab Method for reperfusion therapy
CH680001A5 (de) * 1987-11-19 1992-05-29 Sandoz Ag

Also Published As

Publication number Publication date
EP0429542B1 (de) 1995-12-06
JPH04500076A (ja) 1992-01-09
US5302384A (en) 1994-04-12
EP0429542A1 (de) 1991-06-05
EP0429542A4 (en) 1991-12-11
WO1990001338A1 (en) 1990-02-22
DE68925032D1 (de) 1996-01-18
ATE131071T1 (de) 1995-12-15

Similar Documents

Publication Publication Date Title
DE68925032T2 (de) Leukozyten-adhäsions-inhibitor.
DE69517196T2 (de) Inhibitoren der menschlichen neutrophilenelastase
ATE140968T1 (de) Kultur des wachstumsfaktors der vaskularen endothelialzellen und dns, die dafür kodiert
DE68910627T2 (de) Gasphasen-Alpha-Olefinpolymerisationsverfahren in Anwesenheit eines Aktivitätshemmers.
ATE249421T1 (de) Inhibitoren der alpha4-beta1 vermittelten zelladhäsion
DE69837295D1 (de) Probucolbernsteinsäureester zur Hemmung der Expression von VCAM-1
EP0393445A3 (de) Verwendung von renininhibitorischen Peptiden als Mittel gegen Retroviren
DK0489837T4 (da) Inhibering af lymfocytters adhæsion til vaskulært endotel under anvendelse af en hidtil ukendt interaktion mellem ekstracellulær matrixreceptor og ligand
WO1992015605A3 (en) Inhibitors of human neutrophil elastase and human cathepsin g
DK0402068T3 (da) Polypeptider og polypeptidanaloger med inhiberende virkning mod human elastase
NO934218D0 (no) Inhibitorer av cathepsin G og elastase for forhindring avbindevevsnedbrytning
FI935780A (fi) HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoitoa varten
FI943357A (fi) Puheen lomitussyvyyden suurentaminen yhdessä lyhennetyn viiveen kanssa
DE69316754T2 (de) Schrittweise entfernung von monosacchariden vom reduzierenden ende von oligosacchariden und verwendungen davon
BR9815288A (pt) Composição farmacêutica, processos para inibir a desgranulação de mastócitos, para tratar asma em um paciente, para tratar inflamação em um paciente, para inibir a liberação de citocinas em um paciente, para inibir a liberação de histaminas em um paciente, para inibir a liberação de leucotrienos em um paciente, para reduzir a adesão, migração e agregação de linfócitos, eosinófilos e neutrófilos para um sìtio de inflamação em um paciente, para reduzir a produção de anticorpos ige no sìtio de inflamação em um paciente, para inibir a permeabilidade vascular aumentada no sìtio de inflamação em um paciente, e, para tratar inflamação crÈnica em um paciente.
ES2168095T3 (es) Inhibidores de neutrofilos procedentes de nematodos.
DE69021128D1 (de) Interleukin-1-Inhibitor.
DK0862454T3 (da) CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner
Phillips Interferon-α induces renal dysfunction and injury
ATE233570T1 (de) Verwendung des leukämie-inhibitor-faktor und endothelin antagonisten
IT1241921B (it) Perfezionamenti relativi alla rivelazione di scariche ad arco in cavi.
ATE238062T1 (de) Hemmung von hiv-infektion
FR2698270B1 (fr) Utilisation du 5-méthoxypsoralène dans le traitement du sida.
DE69227089T2 (de) Weizen Alpha-Amylase-Inhibitor zur Behandlung von Diabetes
ATE97134T1 (de) Gasphasen-alpha-olefinpolymerisationsverfahren in anwesenheit eines aktivitaetshemmers.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee